Search Results - "Hipper, A"

Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Nusch, A., Reiser, M., Bernhardt, C., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Rittmeyer, A., Bischoff, H., Waller, C., Thomas, M.

Get full text

Wild type but not ΔF508 CFTR inhibits Na + conductance when coexpressed in Xenopus oocytes by Mall, M., Hipper, A., Greger, R., Kunzelmann, K.

“…Airway epithelial cells bearing mutations of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) possess an increased Na + conductance along…”
Get full text

Mutations in the putative pore-forming domain of CFTR do not change anion selectivity of the cAMP activated Cl− conductance by Hipper, A., Mall, M., Greger, R., Kunzelmann, K.

“…Cystic fibrosis transmembrane conductance regulator (CFTR) apparently forms Cl− channels in apical membranes of secretory epithelial cells. A detailed model…”
Get full text

cAMP stimulation of CFTR-expressing Xenopus oocytes activates a chromanol-inhibitable K+ conductance by Mall, M, Kunzelmann, K, Hipper, A, Busch, A E, Greger, R

“…Cystic fibrosis transmembrane conductance regulator (CFTR) functions as a Cl- channel in a large variety of cells expressing this protein. Recently evidence…”
Get full text

Culture-dependent expression of Na+ conductances in airway epithelial cells by Kunzelmann, K, Kathöfer, S, Hipper, A, Gruenert, D C, Gregner, R

“…According to previous studies, amiloride-sensitive (Amil+) Na+ channels are present in apical membranes of airway epithelial cells. When isolated from intact…”
Get full text

963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315 by Eberhardt, W.E.E., Passlick, B., Stuschke, M., Groeschel, A., Christopoulos, P., Reck, M., Ludwig, P., Hipper, A., Chiabudini, M., Spring, L., Jänicke, M., Andres-Pons, A., Christoph, D.C., Bernhardt, C., Reiser, M., Sebastian, M., Griesinger, F., Thomas, M.

Get full text

1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315) by Sebastian, M., Reck, M., Fischer, R.N., Christoph, D.C.C., Bernhardt, C., von der Heyde, E., Nusch, A., Ludwig, P., Hipper, A., Hanselmann, J., Medinger, T., Binninger, A., Jänicke, M., Christopoulos, P., Elender, C., Bethge, A., Seese, B., Gauler, T.C., Waller, C.

Get full text

1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315) by Sebastian, M., Griesinger, F., von der Heyde, E., Dörfel, S., Wiegand, J.H., Schiefer, C., Losem, C., Jänicke, M., Fleitz, A., Zacharias, S., Hipper, A., Dietel, C., Bleckmann, A., Benkelmann, R., Boesche, M., Grah, C., Müller, A., Eberhardt, W.E.E., Thomas, M.

Get full text

49P EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315) by Griesinger, F., Sebastian, M., Bethge, A., Christopoulos, P., Hoffknecht, P., Waller, C., Benkelmann, R., Jänicke, M., Fleitz, A., Hanselmann, J., Hipper, A., Groth, A., Weichert, W., Nusch, A., Rauh, J., Fietz, T., Illmer, T., Depenbusch, R., Eberhardt, W.E.E., Thomas, M.

Get full text

Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis by Busch, A E, Suessbrich, H, Kunzelmann, K, Hipper, A, Greger, R, Waldegger, S, Mutschler, E, Lindemann, B, Lang, F

“…The three subunits (alpha, beta, gamma) encoding for the rat epithelial Na+ channel (rENaC) were expressed in Xenopus oocytes, and the induced Na+ conductance…”
Get full text

1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315 by Gröschel, A., Passlick, B., Stuschke, M., Christopoulos, P., Reck, M., Grah, C., Groth, A., Hipper, A., Chiabudini, M., Fleitz, A., Jänicke, M., Spring, L., Christoph, D.C., Bernhardt, C., Reiser, M., Zahn, M-O., Sebastian, M., Griesinger, F., Thomas, M., Eberhardt, W.E.E.

Get full text

1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315) by Griesinger, F., Sebastian, M., Brückl, W., Hummel, H-D., Jaeschke, B., Kern, J., Schumann, C., Wesseler, C., Jänicke, M., Fleitz, A., Zacharias, S., Hipper, A., Groth, A., Weichert, W., Dörfel, S., Petersen, V., Schröder, J., Wilke, J., Eberhardt, W.E.E., Thomas, M.

Get full text

Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Bruch, H.-R., Rauh, J., von der Heyde, E., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Sadjadian, P., Metzenmacher, M., Gleiber, W., Sebastian, M., Thomas, M.

Get full text

1500P - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Bruch, H.-R., Rauh, J., von der Heyde, E., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Sadjadian, P., Metzenmacher, M., Gleiber, W., Sebastian, M., Thomas, M.

“…Guidelines for metastatic non-small cell lung cancer recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome…”
Get full text

1552PPatients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Griesinger, F, Eberhardt, W E E, Nusch, A, Reiser, M, Zahn, M-O, Marschner, N W, Jänicke, M, Fleitz, A, Spring, L, Sahlmann, J, Karatas, A, Hipper, A, Weichert, W, Waller, C, Reck, M, Christopoulos, P, Sebastian, M, Thomas, M

“…Abstract Background Guidelines for metastatic non-small cell lung cancer recommend stratified treatment by biomarker test results. We used CRISP to evaluate…”
Get full text

1519P - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M., Eberhardt, W.E.E., Losem, C., Bernhardt, C., Maintz, C., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Hoffknecht, P., Grah, C., Rittmeyer, A., Griesinger, F., Thomas, M.

“…Treatment guidelines for metastatic non-small cell lung cancer recommend stratified treatment according to biomarker testing results. Here we used CRISP to…”
Get full text

1552P - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Nusch, A., Reiser, M., Zahn, M.-O., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Waller, C., Reck, M., Christopoulos, P., Sebastian, M., Thomas, M.

“…Guidelines for metastatic non-small cell lung cancer recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome…”
Get full text

1519PPatients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M, Eberhardt, W E E, Losem, C, Bernhardt, C, Maintz, C, Marschner, N W, Jänicke, M, Fleitz, A, Spring, L, Sahlmann, J, Karatas, A, Hipper, A, Weichert, W, Hoffknecht, P, Grah, C, Rittmeyer, A, Griesinger, F, Thomas, M

“…Abstract Background Treatment guidelines for metastatic non-small cell lung cancer recommend stratified treatment according to biomarker testing results. Here…”
Get full text

Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M., Eberhardt, W.E.E., Losem, C., Bernhardt, C., Maintz, C., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Hoffknecht, P., Grah, C., Rittmeyer, A., Griesinger, F., Thomas, M.

Get full text

Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Nusch, A., Reiser, M., Zahn, M.-O., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Waller, C., Reck, M., Christopoulos, P., Sebastian, M., Thomas, M.

Get full text